NCT06079281: Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
- State
- Under way
- Phase
- Phase 3
- People
- 124 taking part
- Started
- 3 Jan 2024
- Primary completion
- 9 Jul 2025
- Arms
- ALXN1850 Group
- Results
- None posted
- 12 Oct 2023: Trial registered
- 3 Jan 2024: Trial started